Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30366858 | 0.84 | CYP3A4 (0.39) | CYP3A4CYP2D6CYP2C9CNR1CYP2C19 | |
| SCHEMBL3990597 | 0.84 | CYP3A4 (0.39) | CYP3A4CYP2D6CYP2C9CNR1CYP2C19 | |
| SCHEMBL30366512 | 0.82 | CYP3A4 (0.38) | CYP3A4CYP2D6CYP2C9CNR1CYP2C19 | |
| SCHEMBL17546011 | 0.77 | MGLL (0.44) | NR4A2BRD4KDM4EALDH1A1 | |
| SCHEMBL3990376 | 0.77 | CYP3A4 (0.51) | CYP3A4CYP2D6CYP2C9CNR1CYP2C19 | |
| SCHEMBL16336317 | 0.76 | HSP90B1 (0.45) | MAPTABL1GAA | |
| SCHEMBL29709454 | 0.76 | HSP90B1 (0.45) | MAPTABL1GAA | |
| SCHEMBL3990239 | 0.76 | CNR2 (0.68) | CYP3A4CYP2D6CYP2C9CNR1CYP2C19 | |
| SCHEMBL3990861 | 0.76 | KDM4E (0.39) | NR4A2KDM4EALDH1A1MAPTABL1 | |
| SCHEMBL3988996 | 0.76 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C9CNR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894481-A | Nitrogen-containing heteroaryl compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1753764-B1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| EP-1753764-B1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| EP-1753764-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2007017264-A2 | PYRROLOPYRIDINEDERIVATIVES AS MODULATORS OF THE CANNABINOID RECEPTOR FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017264-A2 | PYRROLOPYRIDINEDERIVATIVES AS MODULATORS OF THE CANNABINOID RECEPTOR FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005121140-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219229-A1 | Pyrrolopyridine Derivatives | CNR2, CNR1, TRPV1 | NR4A2 750/4885CYP3A4 1521/4885CYP2D6 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.